Toxicity assessment of Phlogacanthus thyrsiflorus, a traditionally used anthelmintic plant of India

Deori, Khirod; Soren, Amar Deep; Yadav, Arun K.

doi:10.1186/s43094-023-00502-3

Future Journal of Pharmaceutical Sciences

Table 2 Effects of sub-chronic oral administration of P. thyrsiflorus leaf extract (PLE) and acetaminophen (ACP) on some haematological parameters (n = 5/sex)

From: Toxicity assessment of Phlogacanthus thyrsiflorus, a traditionally used anthelmintic plant of India

	G-I Control	G-II PLE 200 mg/kg	G-III PLE 400 mg/kg	G-IV PLE 800 mg/kg	G-V ACP 50 mg/kg	Satellite groups
						G-VI	G-VII	G-VIII
						Control	PLE 800 mg/kg	ACP 50 mg/kg
Female
RBC (/cmm)	7.42 ± 0.05	7.17 ± 0.01	7.52 ± 0.08^e	8.42 ± 0.04^d	6.25 ± 0.53^b	7.67 ± 0.02	7.37 ± 0.02	6.93 ± 0.01
WBC (/cmm)	7600 ± 401	7780 ± 250^d	7500 ± 216^d	7690 ± 488^d	6302 ± 223^a	7500 ± 134	7638 ± 238^h	6980 ± 302^g
Neutr (%)	16.87 ± 0.27	16.67 ± 0.25^d	16.60 ± 0.23^d	16.43 ± 0.19^d	11.11 ± 0.93^a	16.76 ± 0.21	16.38 ± 0.22^h	13.62 ± 0.22^g
Lym (%)	70.6 ± 2.37	73.2 ± 1.3^d	70.18 ± 2.01^d	72.12 ± 1.90^d	54.01 ± 0.71^a	71.51 ± 0.77	73.71 ± 1.33^h	63.74 ± 1.05^g
Eos (%)	4.20 ± 0.58	4.00 ± 0.54	3.40 ± 0.48^f	4.12 ± 0.04	3.65 ± 0.35	3.94 ± 0.11	4.80 ± 0.03	3.79 ± 0.44
Mncs (%)	3.40 ± 0.25	3.60 ± 0.21	3.60 ± 0.21	3.30 ± 0.34	3.60 ± 0.24	3.40 ± 0.35	3.80 ± 0.16	3.60 ± 0.23
PCV (%)	37.73 ± 0.19	37.50 ± 0.06	38.11 ± 0.13	37.57 ± 0.16	34.47 ± 0.21^c	38.23 ± 0.06	37.84 ± 0.36	35.51 ± 0.32
HGB (gm/dL)	14.18 ± 0.04	13.40 ± 0.11^d	13.34 ± 0.14^d	13.60 ± 0.10^d	9.09 ± 0.57^a	13.42 ± 0.02	14.16 ± 0.04^h	10.42 ± 0.02^g
MCV (/cuµ)	51.11 ± 2.02	51.34 ± 0.03^d	50.09 ± 1.50^d	54.75 ± 0.33^d	63.99 ± 1.13^a	56.41 ± 0.30	54.53 ± 0.12ⁱ	59.84 ± 0.09
PLT (× 10²/cmm)	8370 ± 4870	9884 ± 6870^d	8754 ± 3360	9309 ± 5910^f	7136 ± 4860	8260 ± 2091	8572 ± 4120	7848 ± 6440
Male
RBC (/cmm)	8.30 ± 0.02	8.32 ± 0.12^b	8.36 ± 0.11^b	8.18 ± 0.05	7.10 ± 0.07^a	8.13 ± 0.07	8.25 ± 0.18	8.12 ± 0.00
WBC (/cmm)	9147 ± 276	9073 ± 167	8944 ± 268	9289 ± 435	7160 ± 218	8849 ± 715	9205 ± 490	7860 ± 548
Neutr (%)	16.63 ± 0.24	16.89 ± 0.16	15.97 ± 0.29	17.29 ± 0.22	13.38 ± 0.64	16.91 ± 0.25	17.15 ± 0.36	15.36 ± 0.03
Lym (%)	73.40 ± 0.16	74.31 ± 1.06^b	71.60 ± 0.92^b	72.40 ± 0.16^b	63.29 ± 2.15^a	72.80 ± 1.15	70.60 ± 0.92	68.40 ± 1.12
Eos (%)	2.39 ± 0.15	3.10 ± 0.22	2.60 ± 0.40	3.16 ± 0.40	2.60 ± 0.50	2.20 ± 0.73	2.40 ± 0.83	3.00 ± 0.40
Mncs (%)	1.20 ± 0.66	1.23 ± 0.58	1.71 ± 0.48	1.40 ± 0.50	1.60 ± 0.24	1.80 ± 0.24	1.20 ± 0.37	1.40 ± 0.24
PCV (%)	41.18 ± 0.44	42.02 ± 0.33^c	41.00 ± 0.39	42.23 ± 0.26^c	39.00 ± 0.57	41.19 ± 0.64	40.70 ± 0.16	41.37 ± 0.15
HGB (gm/dL)	13.56 ± 0.02	13.90 ± 0.27^b	13.92 ± 0.18^b	14.14 ± 0.04^b	9.10 ± 0.11^a	14.11 ± 0.00	13.98 ± 0.28^j	12.80 ± 0.12^g
MCV (/cuµ)	50.58 ± 1.17	51.55 ± 0.12^b	52.53 ± 0.96^b	50.41 ± 0.08^b	61.00 ± 0.57^a	53.40 ± 0.12	51.21 ± 0.03^j	59.65 ± 0.02^g
PLT (× 10²/cmm)	8404 ± 4800	9170 ± 5622^d	8312 ± 4081	8512 ± 2270	7042 ± 3728	9100 ± 3531	8716 ± 5367	8200 ± 5295

Data are expressed as mean ± S.E.M.; Treatment: G-II to G-V = 4 weeks and G-VII to G-VIII = 6 weeks
Female: ^ap < 0.001, ^bp < 0.01, ^cp < 0.05 as compared to control value; ^dp < 0.001, ^ep < 0.01, ^fp < 0.05 as compared to ACP values; ^gp < 0.001 as compared to satellite control values; ^hp < 0.001, ⁱp < 0.05 as compared to satellite ACP values, one way ANOVA
Male: ^ap < 0.001 as compared to control value; ^bp < 0.001, ^cp < 0.01, ^dp < 0.05 as compared to ACP values; ^gp < 0.001 as compared to satellite control values; ^jp < 0.001 as compared to satellite ACP values, one way ANOVA

Back to article page